Halozyme Therapeutics (Halozyme Therapeutics) Debt-to-EBITDA : 2.95 (As of Dec. 2023)

Halozyme Therapeutics Debt-to-EBITDA Chart

Halozyme Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-EBITDA		Get a 7-Day Free Trial					-7.12	2.60	3.38	4.77	3.32

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															4.57	4.84	3.16	2.90	2.95

Competitive Comparison of Halozyme Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Halozyme Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Debt-to-EBITDA falls into.

Halozyme Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Halozyme Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Halozyme Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Halozyme Therapeutics  (NAS:HALO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Halozyme Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description